Cyclacel Pharmaceuticals, Inc. (BGMS)
NASDAQ
Cyclacel Pharmaceuticals, Inc. Shareholder Equity 2024–2025
Cyclacel Pharmaceuticals, Inc. annual shareholder equity history from 2024 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Cyclacel Pharmaceuticals, Inc. shareholder equity as of December 31, 2025: 6.8M, a 414.72% decrease year-over-year.
- Cyclacel Pharmaceuticals, Inc. shareholder equity for 2025 were 6.8M, a 414.72% decrease from 2024.
- Cyclacel Pharmaceuticals, Inc. shareholder equity for 2024 were -2.2M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Cyclacel Pharmaceuticals, Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $7 |
| 2024 | $-2 |
Cyclacel Pharmaceuticals, Inc. Shareholder Equity — FAQ
Cyclacel Pharmaceuticals, Inc. (BGMS) shareholder equity over the last 2 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see BGMS's shareholder equity history?
The chart and table above show Cyclacel Pharmaceuticals, Inc.'s shareholder equity by year and by quarter, including the growth rate.